Immunomodulatory drugs in chronic lymphocytic leukemia: A new treatment paradigm

References

• Chiorazzi N, Rai K R, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804–815
   PubMed Web of Science ®Google Scholar
• Kay N E, Bone N D, Tschumper R C, Howell K H, Geyer S M, Dewald G W, et al. B-CLL cells are capable of synthesis and secretion of both pro-and anti-angiogenic molecules. Leukemia 2002; 16: 911–916
   PubMed Web of Science ®Google Scholar
• Kay N E, Jelinek D F, Dewald G W. Progression events in B-chronic lymphocytic leukemia. Hematology 2002; 197–203
   PubMedGoogle Scholar
• Novak A J, Bram R J, Kay N E, Jelinek D F. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukaemia cells: a mechanism for survival. Blood 2002; 100: 2973–2979
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Porter C W. Immunomodulating drugs for chronic lymphocytic leukemia. Lancet Oncol 2006; 7: 480–488
   PubMed Web of Science ®Google Scholar
• Yagyu T, Kobayashi H, Matsuzaki H, Wakahara K, Kondo T, Kurita N, et al. Thalidomide inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endometriotic stromal cells, possibly through suppression of nuclear factor-kappa B activation. J Clin Endocrinol Metab 2005; 90: 3017–3021
   PubMed Web of Science ®Google Scholar
• Li X, Liu X, Wang J, Wang Z, Jiang W, Reed E, et al. Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res 2003; 23: 2481–2487
   PubMed Web of Science ®Google Scholar
• Raje N, Anderson K C. Thalidomide and immunomodulatory, drugs as cancer therapy. Curr Opin Oncol 2002; 14: 635–640
   PubMed Web of Science ®Google Scholar
• Davies F E, Raje N, Hideshima T, Lentzsch S, Young G, Tai Y T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytoxicity in multiple myeloma. Blood 2001; 98: 210–216
   PubMed Web of Science ®Google Scholar
• Dredge K, Marriott J B, Dalgleish A G. Immunological effects of thalidomide and its chemical and functional analogs. Crit Rev Immunol 2002; 22: 425–437
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Padmanabhan S, Miller K, Pera P, DiMiceli L, Ersing N, et al. In vivo evaluation of immunomodulating effects of lenalidomide on tumor cell microenvironment a possible underlying mechanism of antitumor effects observed in patients with chronic lymphocytic leukemia. Blood 2005; 106: 834a
   Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571
   PubMed Web of Science ®Google Scholar
• Folkman J, Rogers M S, Barlogie B, Shaughnessy J, Tricot G. Thalidomide for multiple myeloma. N Engl J Med 2006; 354: 2389–2390
   PubMed Web of Science ®Google Scholar
• Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001; 98: 958–965
   PubMed Web of Science ®Google Scholar
• Kay N, Geyer S, Yaqoob I, Phyliky R, Kutteh L, Li C Y. Thalidomide treatment in chronic lymphocytic leukemia: a North Central Cancer Treatment Group (NCCTG) study. Blood 2003; 102: 359b
   Web of Science ®Google Scholar
• Chanan-Khan A, Miller K C, Takeshita K, Koryzna A, Donohue K, Bernstein Z P, et al. Result of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 2005; 106: 3348–3352
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller K C, Musial L, Lawrence D, Padmanabhan S, Takeshita K, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006; 24: 5343–5349
   PubMed Web of Science ®Google Scholar
• Furman R R, Leonard J P, Allen S L, Coleman M, Rosenthal T, Gabrilore J L, et al. Thalidomide alone or in combination with fludarabine are effective treatment for patients with fludarabine-relapsed and refractory CLL. Proc AM Soc Clin Oncol 2005; 6640
   Google Scholar
• Trompeter S, Yong K, Jewell A, Nathwani A. Thalidomide in combination with dexamethasone and cyclophosphamide shows activity in patients with relapsed chronic lymphocytic leukemia. 11th International Workshop on Chronic Lymphocytic Leukemia, Brooklyn, NYUSA, 2005, 88, Abstract
   Google Scholar
• List A, Kurtin S, Roe D J, Buresh A, Mahadevan D, Fuchs D, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549–557
   PubMed Web of Science ®Google Scholar
• Richardson P G, Schlossman R L, Weller E, Hideshima T, Mitsiades C, Davies F, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063–3067
   PubMed Web of Science ®Google Scholar
• Mitsiades C S, Mitsiades N. CC-5013 (Celgene). Curr Opin Investig Drugs 2004; 5: 635–647
   PubMedGoogle Scholar
• Miller K, Czuczman M S, Dimiceli L, et al. Lenalidomide (L) induces high response rates with molecular remission in patients (pts) with relapsed (rel) or refractory (ref) chronic lymphocytic leukemia (CLL). Proc Am Soc Clin Oncol 2006; 6517, Abstract
   Google Scholar
• DiMiceli L, Miller K, Rickert M, Wallace P, Marshall P, DePaolo P, et al. Characterization of IMiDs (immunomodulating agents) induced flare reaction in patients with chronic lymphocytic leukemia (CLL) and correlation with changes in serum cytokine levels. Blood 2005; 106: 344b
   Web of Science ®Google Scholar
• Molica S, Vacca A, Mirabelli R, Ria R, Ribatti D. Angiogenesis in chronic lymphocytic leukemia: an emerging target. Clin Leukemia 2006; 2: 118–122
   Google Scholar